Alectinib

Name: Alectinib | 1256580-46-7
Brand: US-CATO
SKU: S57C4X-2836_5_MG
Price: 19998.0 USD
Availability: InStock

Cat. No S57C4X-2836_5_MG

Vendor: US-CATO

Product Information

Product Name

Alectinib

Brand Name

US-CATO

Product Number

C4X-2836

CAS

1256580-46-7

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

49806720

IUPAC Name

9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzobcarbazole-3-carbonitrile

InChI Key

KDGFLJKFZUIJMX-UHFFFAOYSA-N

SMILES

CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C

References Data Source From Pubchem

Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Publication Name: Nature Communications

Publication Date: 2025-12-12

DOI: 10.1038/s41467-025-59744-9|10.1038/s41467-025-67648-x

A Prompt Diagnosis of Ascites and Dramatic Effect of Alectinib for Advanced Lung Adenocarcinoma Harboring EML4-ALK Fusion

Publication Name: Internal medicine (Tokyo, Japan)

Publication Date: 2025-12-01

DOI: 10.2169/internalmedicine.5397-25

Disproportionality analysis of ALK inhibitor-induced hemolytic adverse events: a pharmacovigilance study using the FDA Adverse Event Reporting System Database

Publication Name: Canadian Journal of Physiology and Pharmacology

Publication Date: 2025-10-01

DOI: 10.1139/cjpp-2025-0065

ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion

Publication Name: Cancer Research and Treatment

Publication Date: 2025-07-15

DOI: 10.4143/crt.2024.1184

Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node

Publication Name: European Journal of Pharmacology

Publication Date: 2025-07-05

DOI: 10.1016/j.ejphar.2025.177527

Alectinib

Product Information

General Information

References Data Source From Pubchem

Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

A Prompt Diagnosis of Ascites and Dramatic Effect of Alectinib for Advanced Lung Adenocarcinoma Harboring EML4-ALK Fusion

Disproportionality analysis of ALK inhibitor-induced hemolytic adverse events: a pharmacovigilance study using the FDA Adverse Event Reporting System Database

ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion

Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node

Alectinib

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

About Us

Popular Searches

Contact

#title#

Features
Availability:
Price
Options
Actions

Alectinib

Product Information

General Information

References Data Source From Pubchem

Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

A Prompt Diagnosis of Ascites and Dramatic Effect of Alectinib for Advanced Lung Adenocarcinoma Harboring EML4-ALK Fusion

Disproportionality analysis of ALK inhibitor-induced hemolytic adverse events: a pharmacovigilance study using the FDA Adverse Event Reporting System Database

ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion

Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node

Alectinib

Related Product

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

#title#

Login

Register